search
Back to results

Adverse Drug Event Prevention Using Structured Pharmacist Review

Primary Purpose

Adverse Drug Reactions

Status
Completed
Phase
Phase 4
Locations
Ireland
Study Type
Interventional
Intervention
Structured expert pharmacist review
No Intervention
Sponsored by
University College Cork
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Adverse Drug Reactions focused on measuring Elderly, Hospital, Adverse Drug, Pharmacist, Prevention

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All patients aged 65 years and over presenting to CUH Accident and Emergency Departments with acute illness for admission under a medical team will be eligible for the study.

Exclusion Criteria:

  1. Age less than 65 years.
  2. Patient to be admitted under the care of a Geriatrician Psychiatrist of Old Age or Clinical Pharmacologist, or having been admitted under these services or attended their outpatient clinics in the previous 12 months. (These doctor groups are likely to minimise inappropriate medications in this population).
  3. Terminally ill patient attended by palliative care team.
  4. Critically ill patient e.g. admitted to Intensive Care Unit.
  5. Patients who do not wish to participate in the study.
  6. Patients whose hospital physician does not wish to participate in the study ver, its efficacy in terms of ADE prevention is not yet demonstrated.

Sites / Locations

  • Cork University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Structured expert pharmacist review

Normal pharmaceutical care in hospital

Arm Description

Outcomes

Primary Outcome Measures

Number of patients with definite and possible adverse drug events during their hospital admission

Secondary Outcome Measures

Drug ingredient cost at hospital discharge
Medication Appropriateness Index score
Composite health resource utilization including hospital admissions and primary care consultations

Full Information

First Posted
September 2, 2011
Last Updated
June 5, 2012
Sponsor
University College Cork
search

1. Study Identification

Unique Protocol Identification Number
NCT01467128
Brief Title
Adverse Drug Event Prevention Using Structured Pharmacist Review
Official Title
Title of Study: Adverse Drug Event (ADE) Incidence in Older Patients Following Hospital Admission and Pharmacist Review to Older Persons' Prescriptions and Its' Effect on ADE Reduction in Hospital: a Randomised Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2012
Overall Recruitment Status
Completed
Study Start Date
June 2011 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
June 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University College Cork

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The next four decades will see a marked expansion of the elderly population in Ireland, in particular people aged over 80 yrs. Persons aged over 80 are the highest consumers of prescription medicines in Ireland and have the highest prevalence rates of major polypharmacy. Polypharmacy is intimately linked with serious adverse drug events (ADEs) and consequent major morbidity and mortality. Epidemiological data from the Unites States indicate that ADEs is the fifth most common cause of death nationally. Experts suggest that effective evidence based interventions can be applied to this major public health problem. A recently described approach to hospitalised older patients' medication optimisation is that of Spinewine and colleagues at Louvain University, Belgium. In this model, a pharmacist with expertise in geriatric pharmacotherapy routinely reviews the prescriptions of older patients from admission to discharge. The pharmacist provides a detailed pharmaceutical care plan for older patients and their carers where appropriate as well as feedback information to prescribers in the event of detecting instances of probable medication inappropriateness. Whenever an opportunity for medication optimisation is identified, the pharmacist discusses the opportunity with the prescriber who can accept or reject the intervention. At discharge from hospital, the pharmacist also provides written and verbal information on treatment changes to the patient / caregiver and GP. The intervention therefore represents a comprehensive pharmaceutical care approach that is based upon careful review and subsequent consensus on individualised pharmacotherapy. In an RCT comparison of this approach with standard care, older patients in the intervention arm of the study had significant improvements in medication appropriateness (medication appropriateness index (MAI), Beers' criteria, and Assessing Care of Vulnerable Elders (ACOVE) criteria.). Expert pharmacist review of older peoples' medication in hospital is a proven intervention in term of reducing inappropriateness of medication.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adverse Drug Reactions
Keywords
Elderly, Hospital, Adverse Drug, Pharmacist, Prevention

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
720 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Structured expert pharmacist review
Arm Type
Active Comparator
Arm Title
Normal pharmaceutical care in hospital
Arm Type
No Intervention
Intervention Type
Other
Intervention Name(s)
Structured expert pharmacist review
Other Intervention Name(s)
expert pharmacist review
Intervention Description
The researcher will apply the pharmacist intervention to the cases randomised to this arm of the study. This consists of an expert pharmacist review of the patients prescribed medications at the time of recruitment into the study. Recommendations following the intervention will be communicated both verbally and in writing to the medical team with primary responsibility for the patient. Recommendations arising from the intervention will be printed out and inserted into the patients' notes, in addition to the relevant registrar being informed in person or via the telephone.
Intervention Type
Other
Intervention Name(s)
No Intervention
Intervention Description
Normal hospital pharmaceutical care
Primary Outcome Measure Information:
Title
Number of patients with definite and possible adverse drug events during their hospital admission
Time Frame
From point of randomization to Day 14
Secondary Outcome Measure Information:
Title
Drug ingredient cost at hospital discharge
Time Frame
Up to Day 14
Title
Medication Appropriateness Index score
Time Frame
measured at Day 14 and again at three months post hospital discharge.
Title
Composite health resource utilization including hospital admissions and primary care consultations
Time Frame
Measured at 3 months post hospital discharge

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients aged 65 years and over presenting to CUH Accident and Emergency Departments with acute illness for admission under a medical team will be eligible for the study. Exclusion Criteria: Age less than 65 years. Patient to be admitted under the care of a Geriatrician Psychiatrist of Old Age or Clinical Pharmacologist, or having been admitted under these services or attended their outpatient clinics in the previous 12 months. (These doctor groups are likely to minimise inappropriate medications in this population). Terminally ill patient attended by palliative care team. Critically ill patient e.g. admitted to Intensive Care Unit. Patients who do not wish to participate in the study. Patients whose hospital physician does not wish to participate in the study ver, its efficacy in terms of ADE prevention is not yet demonstrated.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David O'Sullivan, MPharm
Organizational Affiliation
University College Cork, Ireland
Official's Role
Study Director
Facility Information:
Facility Name
Cork University Hospital
City
Cork
State/Province
Munster
Country
Ireland

12. IPD Sharing Statement

Citations:
PubMed Identifier
16569792
Citation
Spinewine A, Dhillon S, Mallet L, Tulkens PM, Wilmotte L, Swine C. Implementation of ward-based clinical pharmacy services in Belgium--description of the impact on a geriatric unit. Ann Pharmacother. 2006 Apr;40(4):720-8. doi: 10.1345/aph.1G515. Epub 2006 Mar 28.
Results Reference
background
PubMed Identifier
17493184
Citation
Spinewine A, Swine C, Dhillon S, Lambert P, Nachega JB, Wilmotte L, Tulkens PM. Effect of a collaborative approach on the quality of prescribing for geriatric inpatients: a randomized, controlled trial. J Am Geriatr Soc. 2007 May;55(5):658-65. doi: 10.1111/j.1532-5415.2007.01132.x.
Results Reference
background
PubMed Identifier
21670370
Citation
Hamilton H, Gallagher P, Ryan C, Byrne S, O'Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med. 2011 Jun 13;171(11):1013-9. doi: 10.1001/archinternmed.2011.215.
Results Reference
background
Links:
URL
http://hrb.ie
Description
Health Research Board (Ireland) website

Learn more about this trial

Adverse Drug Event Prevention Using Structured Pharmacist Review

We'll reach out to this number within 24 hrs